Kornimate/medical-research-clean huggingface dataset:
red meat, increased iron load and cvd risk

Conditions: Myocardial Infarction; Stroke; Cardiovascular Mortality

Summary: increased iron load could be a risk factor for cardiovascular diseases (cvd). red meat consumption affects iron status and has also been shown to be related to increased cvd risk. the investigators hypothesized that risk associations between red meat intake and cardiovascular disease risk can to some degree be explained by higher iron load among individuals with higher meat intake. thus, the investigators evaluate associations between red meat consumption, iron status, and cvd risk in a large-scale population based study, the european prospective investigation into cancer and nutrition (epic) - heidelberg.

the present study part of the the european prospective investigation into cancer and nutrition (epic) - heidelberg, a large-scale observational cohort study located at the german cancer research center, heidelberg, germany. the study started between 1994 and 1998, when 25 540 adults from the local general population were recruited. study participants are being followed-up by active and passive procedures. the main aim of the study is to evaluate associations between diet, lifestyle as well as metabolism and risks of major chronic diseases (cancer, cardiovascular diseases, diabetes). here, the investigators register a project from within epic-heidelberg on prediagnostic iron status as a potential mediator of associations between pre-diagnostic red meat consumption and cardiovascular disease risk. for this particular project, an embedded case-cohort set-up was chosen, i.e. iron status markers (primary marker: serum ferritin; secondary markers: serum transferrin, serum iron) were measured in baseline blood samples from a random subcohort (n=2738) and all validated incident cases of myocardial infarction (n=556), stroke (n=513), and cvd death (n=327) that occured until the closure date of the present study (12-31-2009). statistical analyses follow four steps to assess whether iron status may mediate associations between red meat consumption and cvd risk, as proposed by wittenbecher et al. (am j clin nutr, 2015: www.ncbi.nlm.nih.gov/pubmed/25948672): 1. multivariable cox regression analyses on red meat consumption and cvd risk, assuming a significant positive association 2. multivariable linear regression analyses on red meat consumption and iron status, assuming a significant positive association 3. multivariable cox regression analyses on iron status and cvd risk, assuming a significant positive association 4. multivariable cox regression analyses on red meat consumption and cvd risk, additionally adjusting for iron status, assuming that the association will be attenuated by adjustment for iron status

Eligibility criteria:
inclusion criteria: general population, age 35-65 years exclusion criteria: prevalent myocardial infraction or stroke
prospective genetic study in patients with ovarian insufficiency

Conditions: Premature Ovarian Failure; Primary Ovarian Insufficiency; Ovarian Dysgenesis; Diminished Ovarian Reserve

Summary: genetic screening and etiological analysis was conducted on patients with ovarian insufficiency and decline in ovarian reserve. all patients were enrolled in the ivf-treated and non-ivf-treated groups, followed up for long-term treatment outcomes and genomic screening.

the cause of ovarian insufficiency and decline in ovarian reserve are not clear, but most researchers think the probable causes are mainly three aspects: chromosomal abnormalities, genetic factors and autoimmune diseases，but the majority of patients with normal chromosome karyotype analysis. the screening of pathogenic genes in patients with normal karyotype is the focus of current premature ovarian insufficiency(poi) and decline in ovarian reserve(dor) etiology, to further explain the pathogenesis of patients, improve the diagnosis of those diseases and clinical treatment.

Eligibility criteria:
inclusion criteria: * patients diagnosed as "premature ovarian insufficiency", "diminished ovarian reserve", "primary amenorrhea", " ovarian dysgenesis", " repeated implantation failure" exclusion criteria: * to rule out polycystic ovary syndrome（pcos）, iatrogenic factors (such as surgery, radiotherapy and chemotherapy, etc.) lead to premature ovarian insufficiency in patients

Keywords: genetic causes etiology poi dor
gut microbiota transplantation in systemic sclerosis

Conditions: Scleroderma, Systemic

Summary: systemic sclerosis (ssc) is a progressive multi-organ disorder with high disease burden. life expectancy in ssc is reduced by 25-40 years, mainly due to cardiopulmonary and gastro-intestinal (gi) disease involvement; and a very poor response to available treatment. aiming to improve treatment for ssc, the resscue project will determine the therapeutic potential of standardized, cultivated gut microbiome transplantation (gmt), and assess the mechanisms by which this novel intervention strategy works. this approach is rationalized by studies indicating that skewed gut microbiomes could act as major, environmental risk factors in ssc; and thereby be rational targets for therapeutic manipulation. resscue is set up as a 4 months randomized double blind trial involving the university hospital in oslo. trial participants will be recruited from the population-based, nationwide ssc cohort. intervention will be by gmt or placebo. primary end point is changes in ssc-related gi parameters , while secondary outcomes include safety, explorative clinical parameters, changes in oral, skin and gut microbiomes, and in immune cell phenotypes.

this is a randomized, double blind clinical trial testing intervention by standardized gmt. the study cohort will include 10 ssc patients with gi symptoms. evaluation of end points is at 16 weeks. the trial is set up with six study visits. patient recruitment, eligibility screening and retrieval of informed consent will be performed at ous before inclusion. at visit 1, and 6 patients will undergo clinical examination, pfts, at all visits clinical examination and sampling of biological material.

Eligibility criteria:
inclusion criteria: * fulfillment of the 2013 ssc classification criteria * objective gi involvement and provide informed consent. exclusion criteria: * severe organ dysfunction (and risk of procedure related complications * recent exposure to antibiotics
study to assess the effectiveness and safety of flector patch for treatment of acute back strain

Conditions: Acute Back Strain

Summary: although approved for minor strains, sprains and contusions, flector patch has not been studied extensively in the setting of acute back strain. this study is being conducted as an initial step in demonstrating the benefit of flector patch specifically for back strain. in particular, this study is expected to provide information about the amount of improvement in back strain among subjects using the flector patch, which may then be used to inform subsequent studies.


Eligibility criteria:
inclusion criteria: participants in the study must: 1. have acute, non-radicular back strain with onset up to 10 days before the first visit 2. have intact, non-damaged skin at the proposed patch application site 3. be untreated or unresponsive to conservative pain treatment regimens and/or opioids 4. have a minimum pain intensity score of four (4) or more on a scale of 1-10 (a rating of zero (0) being "no pain" and a rating of ten (10) being "pain as bad as you can imagine") 5. have a normal neurologic examination exclusion criteria: participants may not be in the study if they: 1. have had surgery or other chronic pain condition within 3 months before first treatment 2. have back pain radiating below the knee at time of enrollment 3. have neuropathic pain or have been treated with gabapentin or pregabalin for neuropathy 4. are being treated for or are known to currently have kidney or liver disease 5. have certain other diseases or are using certain types of other drugs.

Keywords: flectorâ® patch acute back strain
comparison of postoperative pain management in patients undergoing laparoscopic colorectal surgery under enhanced recovery after surgery (eras) program, laparoscopic colorectal surgery without eras and open colorectal surgery

Conditions: Postoperative Pain

Summary: this is a retrospective study to compare postoperative pain intensity in patients going laparoscopic colorectal surgery with enhanced recovery after surgery (eras), without eras and open colorectal surgery.

this study is a matched case-control study. control patients will be matched to eras cases in a 1:1:1 ratio (laparoscopic surgery with eras protocol : laparoscopic surgery without eras protocol : open surgery).

Eligibility criteria:
inclusion criteria: * patients undergoing colorectal surgery under eras program and those with the same sort of laparoscopic surgery without eras program as well as those with open colorectal surgery with complete required recorded data. exclusion criteria: * 1. patients with incomplete required data on record. * 2. those with any major intraoperative or postoperative complications.
study of long term immune responses and safety of the gsk herpes zoster vaccine in healthy subjects

Conditions: Herpes Zoster

Summary: the subjects included in this study are subjects that participated in study nct00434577. these subjects were vaccinated with the candidate herpes zoster (hz) vaccine at month 0 and month 2 and were then followed at month 12, month 24 and month 36 (study nct00434577) for safety and immunogenicity. this long term follow up study (zoster-024 \[114825\]) will evaluate immune responses to and safety of the previously administered candidate hz vaccine at months 48, 60 and 72. the study visits will be scheduled at approximately one year intervals after the first visit in zoster-024. blood samples for the evaluation of cellular and humoral immunity will be taken from all subjects at each visit. information on safety and the occurrence of hz will also be collected during these visits.


Eligibility criteria:
inclusion criteria: * subjects who the investigator believes can and will comply with the requirements of the protocol * previous participation in study nct00434577 as a member of the intermediate dose active vaccine group * written informed consent obtained from the subject exclusion criteria: * having participated in another study at any time after nct00434577 study end in which the subject was exposed to an investigational or non-investigational product or; concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product * administration of immunoglobulins and/or any blood products within the 3 months preceding the first blood draw * having received a vaccine containing some vaccine components, any time after study end of study nct00434577 * having received a vaccine against hz any time after study end of study nct00434577 * subject who did not receive a complete vaccination course of 2 doses of the intermediate dose active vaccine in study nct00434577

Keywords: herpes zoster vaccine safety immunogenicity
cardiovascular impact of obstructive sleep apnea treatment in normotensive patients

Conditions: Obstructive Sleep Apnea

Summary: recent evidences suggest that obstructive sleep apnea (osa) can contribute to cardiovascular disease even in the absence of hypertension. however, there are few data regarding the impact of osa on the prehypertension and masked hypertension in apparently normotensive patients with osa as well as the impact of treatment with continuous positive airway pressure.


Eligibility criteria:
inclusion criteria: * severe osa patients exclusion criteria: * smoking * sustained hypertension * heart failure * diabetes * renal diseases * under use of any medication * under treatment for osa

Keywords: obstructive sleep apnea blood pressure prehypertension masked hypertension
mitrafit- cardinal adjustable mitral repair follow-up international postmarketing surveillance (pms)

Conditions: Mitral Regurgitation

Summary: this study is designed to observe the clinical outcomes of patients requiring mitral repair that were treated with the ce certified cardinal system.


Eligibility criteria:
inclusion criteria: * age \> 18 years * patient is a candidate for mitral valve repair, with our without concomitant procedures. * subject is willing to give informed consent for collection of his/her clinical data. exclusion criteria: * severe organic lesions with retracted chordae * congenital malformations with lack of valvular tissue * severe valvular calcifications * evolving bacterial endocarditis * known sensitivity to nickel or chromium

Keywords: mitral valve annuloplasty mitral regurgitation
safety and feasibility of endovascular cooling device in patients with hypothermic cardiopulmonary resuscitation

Conditions: Cardiac Arrest

Summary: hypothermic resuscitation is proven to be benefit to the cardiac origin cardiac arrest patients for it improve brain recovery dramatically. however, traditional cooling devices and methods, most external cooling methods, include ice blanket, cooling helmet, or ice packing lower the body temperature slowly or inefficiently which make many emergency physicians hesitate to perform hypothermic resuscitation. to improve and promote the practice of hypothermia resuscitation, more efficient temperature control method is necessary. we conduct this clinical trial to evaluate the safety and feasibility of internal cooling catheter and temperature regulatory device, which is approved by fda in neurologic icu for temperature control, in the cardiac arrest patients.

we recruited successful resuscitated nontraumatic cardiac arrest adult patients in the emergency department to evaluate the safety and feasibility of application those invasive internal temperature regulator devices. internal cooling catheter, "icy" , and thermal regulator device, "coolguard 2000" are applied to the patients from femoral vein. we definite 4 stages according to the temperature during the clinical trial: "the cooling phase", "hypothermia phase", "rewarming phase", and "postrewarming phase". the temperature is lowed or elevated by the rate 0.5c/hr during the cooling and rewarming phase, and it is maintained 33 +/- 1 c during hypothermia phase for 12 hours according to the comment of acls. to understand the safety and feasibility, regular blood sampling, bedside eeg and vital monitors, and special sheets are designed to document the every reasons, time points or every clinical events during hypothermia therapy. the patients is observed until rewarming finish for 48 hours or till death if expired during post-resuscitation hypothermia therapy.

Eligibility criteria:
inclusion criteria: * non-traumatic collapsed patients, whose pulsation continues and persists more than 5 minutes after return of spontaneous circulation from cardiopulmonary resuscitation and consciousness level is less than gcs 5 points. exclusion criteria: * 1. age \> 78 y/o or \ 38 ℃ after resuscitation 3. pregnancy 4. underline terminal malignancy disorder or refuse aggressive treatment cancer patient 5. massive bleeding, known coagulopathy, or received regular anticoagulant medication 6. persisted hypotension ( mean arterial bp \< 60 mmhg) after resuscitation even under inotropic agents 7. no bed available in icu
establishment and evaluation of a post caesarean acute pain service (pcaps)

Conditions: The Efficacy of Analgesic Methods After Caesarean Section

Summary: the aim of this study is to compare the efficacy of analgesic methods after caesarean section before and after post caesarean acute pain service establishing.


Eligibility criteria:
inclusion criteria: * caesarean section performed from october 2009 to october 2011 (study period) * completed "evaluation of postoperative analgesia after caesarean section" form. exclusion criteria: * not completed "standard evaluation of postoperative analgesia after caesarean section" form.

Keywords: acute pain service postoperative analgesia caesarean section non-opioid analgesia opioid analgesia epidural analgesia
causal associations between allergic rhinitis and asthma

Conditions: Allergic Rhinitis; Asthma

Summary: this study investigates the causal relationship between allergic rhinitis and asthma using a bidirectional two-sample mendelian randomization approach. genetic data were derived from uk biobank for allergic rhinitis and from finnish biobank for asthma. this analysis aims to clarify the potential causal link between these two conditions.

this observational study utilizes a bidirectional two-sample mendelian randomization (mr) analysis to examine the causal association between allergic rhinitis and asthma. the genetic data for allergic rhinitis were obtained from the uk biobank, encompassing 18,934 cases and 64,595 controls, while asthma data were derived from a finnish biobank, including 20,629 cases and 135,449 controls. the mendelian randomization analysis was performed using inverse-variance weighting (ivw), mendelian randomization-egger (mr-egger), and weighted median methods to ensure robust causal inference. additional tests, such as cochrane's q test and mendelian randomization pleiotropy residual sum and outlier (mr-presso), were applied to assess heterogeneity and pleiotropy, enhancing the reliability of the findings. the results are expected to provide insights into the bidirectional causal relationship between allergic rhinitis and asthma, potentially informing future prevention and treatment strategies.

Eligibility criteria:
inclusion criteria: * individuals diagnosed with allergic rhinitis or asthma. * availability of genetic data in the uk biobank or finnish biobank. exclusion criteria: * individuals without genetic data. * participants with incomplete phenotype or genotype data.

Keywords: mendelian randomization genetic association bidirectional causality genome-wide association study (gwas) respiratory diseases
dose-effect relationship of rt-pa on ich evacuation

Conditions: Hypertensive Intracerebral Hemorrhage

Summary: the purpose of this trial is to determine the optimal dose of rt-pa in the treatment of intracerebral hemorrhage (ich) using a combination of minimally invasive surgery and clot lysis with rt-pa。

the minimally invasive surgery (mis) plus recombinant tissue plasminogen activator (rt-pa) is one of the best choices in the treatment of a large-scale deep supratentorial intracerebral hematoma. it uses hardware access technology, in a relatively short time to enter the hematoma center with favourable accuracy and safety. the dose of rt-pa range from 0.3 mg to 4.0 mg in different research。we propose to determine the optimal dose of rt-pa with three dose control groups.

Eligibility criteria:
inclusion criteria: * age 18-80. * gcs \ or equal to 6. * spontaneous supratentorial ich ≥ 20 ml diagnosed using radiographic imaging (ct, cta, etc.) * symptoms less than 24 hours prior to diagnostic ct(dct) scan (an unknown time of symptom onset is exclusionary). * six-hour clot size equal to the most previous clot size (within 5 ml) as determined by additional ct scans at least 6 hours apart using the abc/2 method. * intention to initiate surgery between 12 and 72 hours after after diagnostic ct. first dose can be given within 76 hours after dct (delays for post surgical stabilization of catheter bleeding). * sbp \< 180 mmhg sustained for 6 hours recorded closest to time of randomization. * historical rankin score of 0 or 1. * negative pregnancy test. exclusion criteria: * infratentorial hemorrhage (any involvement of the midbrain or lower brainstem as demonstrated by radiograph or complete third nerve palsy). * irreversible impaired brain stem function (bilateral fixed, dilated pupils and extensor motor posturing), gcs ≤ 4. * intraventricular hemorrhage requiring treatment with extraventricular drainage (obstruction of third and fourth ventricles). * ruptured aneurysm, arteriovenous malformation (avm), vascular anomaly, moyamoya disease diagnosed with radiographic imaging. * any irreversible coagulopathy or known clotting disorder. or having the experience of the use of anticoagulant drug. * platelet count \ 1.7, or an elevated prothrombin time (pt) or activated partial thromboplastin time (aptt). * positive urine or serum pregnancy test in pre-menopausal female subjects without a documented history of surgical sterilization. * any concurrent serious illness that would interfere with the safety assessments including hepatic, renal, gastroenterologic, respiratory, cardiovascular, endocrinologic, immunologic, and hematologic disease. * historical rankin score greater than or equal to 2.

Keywords: intracerebral hemorrhage minimally invasive surgery recombinant tissue plasminogen activator dose-effect relationship
pediatric pulmonary and cardiovascular complications of vertically transmitted hiv infection (p2c2)

Conditions: Acquired Immunodeficiency Syndrome; Lung Diseases; Cardiovascular Diseases; Heart Diseases; Heart Failure; HIV Infections; Cytomegalovirus Infections; Pneumocystis Carinii Infections; Ebstein-Barr Virus Infections

Summary: to determine the prevalence and natural history of pulmonary and cardiac complications associated with hiv infection in utero, in infancy, and during early childhood.

background: in 1982, a year after the discovery of aids in adults, cases were described in children. subsequent reports clearly indicated that pulmonary and cardiac diseases contributed significantly to morbidity and mortality in children infected with the human immunodeficiency virus. the initiative was developed by the staff of the division of lung diseases and the division of heart and vascular diseases after consultation with members of the pulmonary, cardiology, and pediatric communities. the request for proposals was released in august 1988 and awards made in may 1989. design narrative: in this prospective natural history study, research was conducted on the response of the immature lung to pneumocystis carinii and other opportunistic lung infections, as well as on the etiology and pathogenesis of lymphocytic pulmonary disorders. the types, incidence, course, outcome, and origin of cardiac disorders were also determined. in addition to the pulmonary and cardiovascular measurements, data on the effects of co-infection with other viruses, cmv and ebv, were obtained. enrollment of participants began in may 1990 and continued through april 1993 in group i and through january 1994 for group ii. the cohort was followed at specified intervals for an additional three years beyond the end of recruitment for clinical examination, cardiac, pulmonary, immunologic, and infectious studies and for intercurrent illnesses (the cohorts were followed through january 1997). follow-up ranged from 2.5 to 6.6 years. the study ends in july 2002. analysis of the database, preparation of manuscripts and follow-up of adult type pulmonary function studies in infants currently followed at sites conducting the womens \& infants transmission study (wits) continue through july 2002

Eligibility criteria:
no eligibility criteria